ENDEAVOUR SILVR

 EXKのチャート


 EXKの企業情報

symbol EXK
会社名 Endeavour Silver Corp (ENDEAVOUR SILVR)
分野(sector)   
産業(industry)   
業種 貴金属_鉱物   原材料・素材(Materials)
概要 エンデバー・シルバー(Endeavour Silver Corp.)はメキシコで銀採掘物件の評価・買収・探査・開発・開拓に従事するほか、チリで探査に従事する。同社の生産鉱山はグアナセビ鉱山、ボラニトス鉱山とエルクーボを含む。グアナセビ鉱山プロジェクトとボラニトス鉱山プロジェクトは事業活動の主要な焦点とする。エルクーボは中央メキシコの歴史的グアナフアト鉱山地区の南東部にある産銀・金鉱山であり、グアナフアト地区の北西部にある同社の運営ボラニトス銀・金鉱山からただ10キロに位置する。平成24年7月13日、同社はAuRico Gold Inc. (AuRico)からMexgold Resources Inc.(Mexgold)及びCompania Minera del Cubo S.A. de C.V.、AuRico Gold GYC S.A. de C.V.とMetales Interamericanos S.A. de C.V.という完全子会社3社に対する買収を完了した。  エンデバ―・シルバ―は、カナダの銀生産会社。子会社を通じ、メキシコの鉱山を評価、取得、探鉱、開発し、銀や金を搾取する。メキシコの採掘作業中の鉱山には、ドゥランゴ州のグアナセビおよびグアナファト州のボラニトスとエル・クボがあり、地下鉱山からの銀・金を生産する。バンク―バ―に本社を置く。  
本社所在地 Suite 1130 609 Granville Street Vancouver British Columbia V7Y 1G5 CAN
代表者氏名 Geoffery Arthur Handley
代表者役職名 Independent Chairman of the Board
電話番号 +1 604-685-9775
設立年月日 29646
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 1615人
url www.edrsilver.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 21.27600
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 326.76950
売上高 (百万ドル) 150.50900
企業価値(EV) (百万ドル) 293.30550
当期純利益 (百万ドル) -12.43900
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Endeavour Silver Corp revenues remained flat at $150.5M. Net loss totaled $12.4M vs. income of $9.7M. Revenues reflect El Cubo segment increase of 22% to $71.5M also reflect Bolanitos segment decrease of 18% to $39.8M Guanacevi segment decrease of 10% to $39.2M. Net loss reflects Salaries wages and benefits increase of 36% to $3M (expense).

 EXKのテクニカル分析


 EXKのニュース

   Cathie Wood’s ARK ETF raises stake in Exact Sciences  2021/06/01 13:18:58 Seeking Alpha
   Green's Portfolio - May 2021  2021/05/31 21:40:32 Seeking Alpha
   Endeavour Silver Corp. Shares Close in on 52-Week High - Market Mover  2021/05/21 22:30:00 Kwhen Finance
Endeavour Silver Corp. (EXK) shares closed today at 0.3% below its 52 week high of $7.10, giving the company a market cap of $1B. The stock is currently up 39.5% year-to-date, up 260.5% over the past 12 months, and up 100.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Trading volume this week was 32.7% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Materials industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 3166.2% The company's stock price performance over the past 12 months beats the peer average by 465.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Cologuard® CRC Screening Test Most Cost-Effective Test in Medically Underserved Alaska Native People  2021/04/28 10:00:00 Benzinga
MADISON, Wis. , April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS ) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most cost-effective colorectal cancer (CRC) screening option in the Alaska Native population, as compared to colonoscopy and the fecal immunochemical test (FIT), for a wide range of adherence scenarios. According to the model, Cologuard produced the highest number of quality adjusted life years (QALYs) gained and the largest reduction in CRC incidence. 1 Colorectal cancer is the second leading cause of cancer death for men and women in the United States , 2 in part because many cancers go undetected until later stages when treatment is less effective. 3 Alaska Native (AN) people have among the nation's highest reported incidence rates for CRC, at 89.0 per 100,000 people compared to 45.7 per 100,000 people for the entire United States . 4 Despite the clear need, screening AN people presents significant challenges, such as lower sensitivity for cancer and pre-cancer with other stool-based tests and obstacles around getting people from their remote homes to healthcare facilities, which requires significant time, expense, and support personnel. 5 The Cologuard test provides a path to overcome these barriers by offering patients a CRC screening test that allows them to collect their sample at home.
   Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know  2021/03/29 15:16:06 Benzinga
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU ), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp (OTC: SFTBY ), T. Rowe Price, Illumina, Inc. (NASDAQ: ILMN ), Novartis AG (NYSE: NVS ) and accounts advised by Ark Invest. Kevin Conroy, the CEO of EXACT Sciences Corporation (NASDAQ: EXAS ) will join the board of directors after the merger is complete. Current shareholders of CM Life Sciences II will own 14% of the company after the merger. PIPE investors will own 20% of the company after the merger. About SomaLogic: Using … Full story available on Benzinga.com
   Jamie Foxx, Stand Up To Cancer And Exact Sciences Launch PSA To Increase Awareness Of Colorectal Cancer  2021/03/17 16:30:00 PR Newswire
LOS ANGELES, March 17, 2021 /PRNewswire-HISPANIC PR WIRE/ -- Academy Award® winner Jamie Foxx has joined Stand Up To Cancer® (SU2C) and Exact Sciences for a new public service announcement (PSA), which raises awareness about colorectal cancer screenings, early detection and prevention,…
   Mad Money Lightning Round: Beyond Meat, Teladoc Health, More  2021/03/16 12:00:00 The Street
Jim Cramer's bullish on Beyond Meat, Teladoc, Exact Sciences and more.
   Global Clinical Next-Generation Sequencing (NGS) Market Report 2021 Featuring ArcherDx, AstraZeneca, BioNTech, Exact Sciences, Grail, Illumina, Invitae, Moderna, Pfizer & Thrive Earlier Detection  2021/03/10 16:15:00 PR Newswire
DUBLIN, March 10, 2021 /PRNewswire/ -- The "Companion Diagnostics (CDx) is Revolutionizing the Global Clinical Next-Generation Sequencing (NGS) Market" report has been added to ResearchAndMarkets.com's offering. 2020 will be remembered for the COVID-19 pandemic, masks, social distancing…
   Ark Funds, Illumina Invest In SomaLogic SPAC Deal: What Investors Should Know  2021/03/29 15:16:06 Benzinga
A leader in the proteomics field is going public with a SPAC deal announced Monday. The SPAC Deal: SomaLogic announced a SPAC deal with CM Life Sciences II Inc (NASDAQ: CMIIU ), valuing the company at $1.2 billion. A $375 million PIPE on the SPAC merger includes investments from SoftBank Group Corp (OTC: SFTBY ), T. Rowe Price, Illumina, Inc. (NASDAQ: ILMN ), Novartis AG (NYSE: NVS ) and accounts advised by Ark Invest. Kevin Conroy, the CEO of EXACT Sciences Corporation (NASDAQ: EXAS ) will join the board of directors after the merger is complete. Current shareholders of CM Life Sciences II will own 14% of the company after the merger. PIPE investors will own 20% of the company after the merger. About SomaLogic: Using … Full story available on Benzinga.com
   Jamie Foxx, Stand Up To Cancer And Exact Sciences Launch PSA To Increase Awareness Of Colorectal Cancer  2021/03/17 16:30:00 PR Newswire
LOS ANGELES, March 17, 2021 /PRNewswire-HISPANIC PR WIRE/ -- Academy Award® winner Jamie Foxx has joined Stand Up To Cancer® (SU2C) and Exact Sciences for a new public service announcement (PSA), which raises awareness about colorectal cancer screenings, early detection and prevention,…
   Mad Money Lightning Round: Beyond Meat, Teladoc Health, More  2021/03/16 12:00:00 The Street
Jim Cramer's bullish on Beyond Meat, Teladoc, Exact Sciences and more.
   Global Clinical Next-Generation Sequencing (NGS) Market Report 2021 Featuring ArcherDx, AstraZeneca, BioNTech, Exact Sciences, Grail, Illumina, Invitae, Moderna, Pfizer & Thrive Earlier Detection  2021/03/10 16:15:00 PR Newswire
DUBLIN, March 10, 2021 /PRNewswire/ -- The "Companion Diagnostics (CDx) is Revolutionizing the Global Clinical Next-Generation Sequencing (NGS) Market" report has been added to ResearchAndMarkets.com's offering. 2020 will be remembered for the COVID-19 pandemic, masks, social distancing…
   Sarah Condella Sells 1,679 Shares of Exact Sciences Co. (NASDAQ:EXAS) Stock  2021/03/06 12:03:24 Watchlist News
Exact Sciences Co. (NASDAQ:EXAS) SVP Sarah Condella sold 1,679 shares of the firm’s stock in a transaction that occurred on Tuesday, March 2nd. The stock was sold at an average price of $138.42, for a total value of $232,407.18. Following the sale, the senior vice president now directly owns 75,731 shares of the company’s stock, […]

 関連キーワード  (貴金属_鉱物 米国株 ENDEAVOUR SILVR EXK )

 twitter  (公式ツイッターやCEOツイッターなど)